April 22, 2021
Business News

Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)


NEW YORK–()–Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) or certain of its officers and directors violated federal securities laws. If you purchased or otherwise own FibroGen stock, and have suffered a loss, you are encouraged to contact Jonathan Zimmerman at (888) 398-9312, or at [email protected] for more information.

In November 2019, AstraZeneca and FibroGen presented results from a pooled safety analysis of six phase 3 trials purportedly showing that FibroGen’s potential first-in-class anemia therapy, Roxadustat, was comparable…



Click here to view the original article.

Related Posts

You might also like ...

KB Home Releases Its 14th Annual Sustainability Report, the Longest-Running Publication of Its Kind in the Homebuilding Industry
AM Best Upgrades Credit Ratings of Investors Heritage Life Insurance Company
Banc of California Reports First Quarter 2021 Financial Results